Christopher Hite
Vermögen: 178 Mio $ am 31.05.2026
Vermögen: 178 Mio $ am 31.05.2026
Christopher Hite is Vice Chairman & Executive Vice President at RP Management LLC and Royalty Pharma Plc since 2020.
Holds director roles at FasterCures, Vera Therapeutics, Inc. (starting 2026), Kailera Therapeutics, Inc. (starting 2025), and serves as a Trustee at Lehigh University.
Formerly Independent Director at Acceleron Pharma, Inc. (2020-2021), Global Head-Healthcare Investment Banking at Lehman Brothers Holdings, Inc. (2007-2008), Global Head-Healthcare at Citigroup, Inc. (2008-2020), and held a Global Head-Healthcare position at Community IT Innovators, Inc. Education includes graduate and MBA degrees from the University of Pittsburgh and an undergraduate degree from Lehigh University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ROYALTY PHARMA PLC 5.05% | 06.04.2026 | 1’238’789 ( 5.05% ) | 69 Mio $ | 31.05.2026 |
| 06.04.2026 | 866’410 ( 0.36% ) | 48 Mio $ | 31.05.2026 | |
| 06.05.2026 | 779’399 ( 0.18% ) | 43 Mio $ | 31.05.2026 | |
RPI US Partners 2019 LP
RPI US Partners 2019 LP Financial ConglomeratesFinance Functions as an investment fund 0.14% | 14.02.2025 | 300’000 ( 0.14% ) | 17 Mio $ | 31.05.2026 |
-.--% | 16.04.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| 24.03.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ROYALTY PHARMA PLC | Corporate Officer/Principal | 01.03.2020 |
| VERA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 05.03.2026 |
RP Management LLC
RP Management LLC Financial ConglomeratesFinance Provides biopharma royalty transactions services | Direktor/Vorstandsmitglied | 01.03.2020 |
FasterCures | Direktor/Vorstandsmitglied | - |
Lehigh University
Lehigh University Other Consumer ServicesConsumer Services Functions as a College/University | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| ACCELERON PHARMA INC. | Direktor/Vorstandsmitglied | 19.11.2021 |
| CITIGROUP INC. | Corporate Officer/Principal | 01.03.2020 |
Lehman Brothers Holdings, Inc.
Lehman Brothers Holdings, Inc. Financial ConglomeratesFinance Provides financial and investment banking services | Corporate Officer/Principal | 01.09.2008 |
Community IT Innovators, Inc.
Community IT Innovators, Inc. Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Lehman Brothers Holdings, Inc.
Lehman Brothers Holdings, Inc. Financial ConglomeratesFinance Provides financial and investment banking services | Finance |
Citigroup, Inc.
Citigroup, Inc. Major BanksFinance Provides retail, investment, commercial banking, brand cards, securities sale & exchanges services | Finance |
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company which develops protein therapeutics for cancer and orphan diseases | Health Technology |
University of Pittsburgh
University of Pittsburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lehigh University
Lehigh University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FasterCures | |
RP Management LLC
RP Management LLC Financial ConglomeratesFinance Provides biopharma royalty transactions services | Finance |
Community IT Innovators, Inc.
Community IT Innovators, Inc. Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Commercial Services |
Royalty Pharma Plc
Royalty Pharma Plc Pharmaceuticals: MajorHealth Technology Buys and operates a portfolio of biopharmaceutical royalties | Health Technology |
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen